Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
Cancer Genetics|December 28, 2011
Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromesKathryn A Kolquist, Roger A Schultz, Aubry Furrow, et al.
Frontiers in Immunology|February 20, 2026
T cell and monocyte activation in concert with hematopoietic stem cell interactions shapes the post-allogeneic transplant immune landscape in poor graft functionAshvind Prabahran, Zhijie Wu, Shouguo Gao, et al.
Leukemia|July 30, 2026
Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppressionC D'Souza, Niko Thio, Ruiqing Zhu, et al.
Cell Reports|February 3, 2016
The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell LymphomaDavid M Wong, Lingli Li, Sabine Jurado, et al.
Cellular and Molecular Life Sciences : CMLS|August 14, 2023
Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapiesTom C Karagiannis, Meaghan Wall, Katherine Ververis, et al.
The EMBO Journal|July 30, 2004
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiationGretchen Poortinga, Katherine M Hannan, Hayley Snelling, et al.
Blood|June 16, 2018
Srsf2 initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cellsMonique F Smeets, Shuh Ying Tan, Jane Jialu Xu, et al.
Blood|May 6, 2017
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxMary Ann Anderson, Constantine Tam, Thomas E Lew, et al.
British Journal of Haematology|August 24, 2021
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic targetClare Gould, Jennifer Lickiss, Yamuna Kankanige, et al.
Cancer Discovery|May 17, 2019
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Natalie Brajanovski, Donald P Cameron, et al.
Pageof 16